iShares Biotechnology ETF (IBB)
| Assets | $8.21B |
| Expense Ratio | 0.44% |
| PE Ratio | 21.96 |
| Shares Out | 49.05M |
| Dividend (ttm) | $0.39 |
| Dividend Yield | 0.22% |
| Ex-Dividend Date | Mar 17, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | 4.82% |
| Volume | 1,255,003 |
| Open | 176.33 |
| Previous Close | 174.12 |
| Day's Range | 175.50 - 177.34 |
| 52-Week Low | 116.25 |
| 52-Week High | 179.64 |
| Beta | 0.79 |
| Holdings | 259 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
45.19% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 7.47% |
| Amgen Inc. | AMGN | 7.23% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.04% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.75% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 3.74% |
| argenx SE | ARGX | 3.38% |
| Insmed Incorporated | INSM | 2.71% |
| Natera, Inc. | NTRA | 2.30% |
| Biogen Inc. | BIIB | 2.29% |
| Revolution Medicines, Inc. | RVMD | 2.29% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 17, 2026 | $0.12182 | Mar 20, 2026 |
| Dec 16, 2025 | $0.1831 | Dec 19, 2025 |
| Sep 16, 2025 | $0.08284 | Sep 19, 2025 |
| Mar 18, 2025 | $0.12117 | Mar 21, 2025 |
| Dec 17, 2024 | $0.06237 | Dec 20, 2024 |
| Sep 25, 2024 | $0.20047 | Sep 30, 2024 |
Performance
IBB had a total return of 50.34% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.01%.
News
Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground
NVIDIA Corp.'s (NASDAQ: NVDA) and Eli Lilly and Co.'s (NYSE: LLY) newly announced $1 billion AI co-innovation lab underscores how artificial intelligence is spreading beyond data centers into medicine...
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Pharma stocks are set to take off this year, says UBS' Michael Yee
Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus
The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to cho...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Trade Tracker: Jason Snipe buys the IBB
Jason Snipe, Founder and CIO of Odyssey Capital Advisors joins CNBC's “Halftime Report” to detail his latest purchase of the IBB.
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Fast Money: WTI, IBB, UBER, CAT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
Political pressure and persistently high interest rates have some wondering if the industry's model is broken.
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
How tariffs could impact pharma and early-stage healthcare investments
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se...
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Health care stocks jump on Trump's nominee for FDA head
CNBC's Angelica Peebles joins 'Fast Money' to talk president-elect Trump's pick for FDA head.
Final Trade: Euro, IBB, SMH, NEM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: West Pharma, Cameco, iShares Biotechnology ETF and Applied Digital Corp
The final trades of the day with the Fast Money traders.
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.
Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.
Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross
Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.
Analyst is 'extremely bullish' on biopharma
Pfizer (PFE) and Merck (MRK) reported their second quarter earnings, with both companies beating expectations. Grey Ghost Advisors CEO Meghan Fitzgerald joins Catalysts to give insight into Pfizer and...
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Biotech's Next Gold Rush: Weight-Loss Drugs
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
Navigating the big run in biotech
The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.
Health care's underperformance last year sets it up well for 2024, says Mara Goldstein
Mara Goldstein, Biotech Analyst at Mizuho, discusses health care's outperformance this week.
Dr. Scott Gottlieb talks Big Pharma's buying spree
Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
Buy or bail on biotech: Here's what you need to know
Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.
Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down
Shares have gotten a boost from the Fed and from M&A.
Wells Fargo's top pharma picks for 2024
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
We see Big Pharma going after smaller biotechs in 2024, says Jefferies' Michael Yee
Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss the state of the biotech industry, impact of interest rate environment on the sector, growth outlook in 2024, obesity drug ...